Bridging the gap between evidence and clinical practice for migraine headaches: a systematic review (2019-2024)
Abstract
BACKGROUND: Migraine headache (MH) is a prevalent and complex neurological disorder affecting over one billion individuals worldwide, making it one of the leading causes of years lived with disability. Randomized controlled trials (RCTs) support evidence-based neurology, but whether recent trials provide practice-ready information remains unclear. This study aims to identify common shortcomings in design and reporting; highlight trial features that enhance value to practicing clinicians; and offer recommendations that improve the alignment between MH research and patient-centered care.
METHODS: We systematically reviewed RCTs focused on acute or preventive MH interventions indexed in Embase and MEDLINE from January 1, 2019, to December 31, 2024, against a 13-item usefulness criteria that captures clinical utility and transparency. Published RCT search filters were adapted from Cochrane strategies, and the complete strategy is available on Open Science Framework (OSF). Trial characteristics and usefulness predictors were analyzed via descriptive statistics and linear regression models. Risk of bias assessment was not performed due to the unavailability of the planned tool. Our evaluation may be influenced by subjectivity in valuing certain clinical utility criteria.
RESULTS: Our systematic review of 169 MH RCTs reveals a field marked by slow yet measurable progress: while over half (50.9%) surpassed the midpoint on the usefulness scale, fewer than 2% met the threshold for…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.